TCM
AGIO icon

TCG Crossover Management’s Agios Pharmaceuticals AGIO Stock Holding History

TCG Crossover Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,181,841
Closed -$32.2M – 50
2025
Q4 		$32.2M Sell
1,181,841
-248,200
-17% -$8.71M 1.06% 26
2025
Q3 		$57.4M Buy
1,430,041
+733,038
+105% +$27.6M 2.82% 11
2025
Q2 		$23.2M Buy
+697,003
New +$21.1M 2.65% 18

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

TCG Crossover Management's AGIO Position: Q1 2026 in Review

TCG Crossover Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 1,181,841 shares — an estimated $32.2M sold.

TCG Crossover Management first reported a position in AGIO in Q2 2025 and held it in 3 quarters. The position peaked at $57.4M in Q3 2025. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • TCG Crossover Management reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • TCG Crossover Management sold 1,181,841 Agios Pharmaceuticals shares in Q1 2026, an estimated $32.2M.
  • TCG Crossover Management first reported a position in Agios Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • TCG Crossover Management's Agios Pharmaceuticals position peaked at $57.4M in Q3 2025.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.